NCT04092751 is a Phase 1 clinical trial of PRA in Pharmacokinetics, sponsored by Scynexis, Inc..

Who is sponsoring NCT04092751?

NCT04092751 is sponsored by Scynexis, Inc..

What drugs are being tested in NCT04092751?

Interventions in NCT04092751: PRA, SCY-078 plus PRA.

What condition does NCT04092751 study?

NCT04092751 studies Pharmacokinetics.

Is NCT04092751 still recruiting?

NCT04092751 is currently completed. Last updated 2 September 2020.

Last reviewed 2020-09-02 · How we verify

NCT04092751

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects

Completed Phase 1 Last updated 2 September 2020

What this trial tests

Phase 1 trial testing PRA in Pharmacokinetics in 28 participants. Completed in 20 December 2019.

Timeline

22 November 2019

Primary endpoint
20 December 2019

20 December 2019

Quick facts

Lead sponsor	Scynexis, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	28
Start date	22 November 2019
Primary completion	20 December 2019
Estimated completion	20 December 2019
Sites	1 location across Australia

Drugs / interventions tested

PRA — full drug profile →
SCY-078 plus PRA — full drug profile →

Conditions studied

Pharmacokinetics — all drugs for Pharmacokinetics →

Sponsor

Scynexis, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Effect of Oral Doses of SCY-078 (Ibrexafungerp) on the Pharmacokinetics of Pravastatin Administered Orally to Healthy Subjects

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.
Hoenigl M, Arastehfar A, Arendrup MC, Brüggemann R, et al · · 2024 · cited 86× · PMID 38602408 · DOI 10.1128/cmr.00074-23
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.
Jallow S, Govender NP. · · 2021 · cited 86× · PMID 33668824 · DOI 10.3390/jof7030163
Antifungal resistance, combinations and pipeline: oh my!
Stover KR, Hawkins BK, Keck JM, Barber KE, et al · · 2023 · cited 10× · PMID 38021410 · DOI 10.7573/dic.2023-7-1
Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science.
Walley AH, Dupuis LN, Woodahl EL, Killam SR. · · 2025 · cited 2× · PMID 40970688 · DOI 10.1111/cts.70362

Verify or expand the search:

Other recruiting trials for Pharmacokinetics

Currently open trials in the same condition.

NCT07583407 — Pharmacokinetics of Kava and Kratom Alone and in Combination · NA · recruiting
NCT07422285 — Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Do · Phase 1 · recruiting
NCT07060209 — Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults · Phase 1 · recruiting
NCT06859723 — High Potency Cannabis: Acute and Protracted Effects · Phase 1 · recruiting
NCT06733675 — Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination · Phase 1 · recruiting

Other Scynexis, Inc. trials

Trials by the same sponsor.

NCT06954493 — Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp · Phase 1 · completed
NCT05668429 — ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects · Phase 1 · completed
NCT05178862 — A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed b · Phase 3 · terminated
NCT05908682 — Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes · recruiting
NCT05399641 — Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04092751 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Scynexis, Inc.
Last refreshed: 2 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04092751.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing